關(guān)鍵詞

巴豆?；?基因變異 免疫 PD-1/PD-L1抗體 炎癥 蛋白 單克隆抗體

?

#今日行業(yè)熱點#

①Nature：Lysine catabolism reprograms tumour immunity through histone crotonylation

通過基因操作或賴氨酸限制降低組蛋白賴氨酸巴豆?；?/span>抑制腫瘤生長

DOI:?10.1038/s41586-023-06061-0

②Genetics in Medicine ：Biallelic variants in Ribonuclease Inhibitor (RNH1), an inflammasome modulator, are associated with a distinctive subtype of acute necrotizing encephalopathy

核糖核酸酶抑制劑(RNH1)的雙等位基因變異體可導致對一種獨特急性壞死性腦病（ANE）亞型的易感性

DOI: 10.1016/j.gim.2023.100897

③Immunological Reviews：Insights into phenotypic and functional CD8+ TRM heterogeneity

綜述：CD8+ TRM異質(zhì)性的單細胞分子譜的新發(fā)現(xiàn)及其對免疫保護和免疫策略設計的潛在影響

DOI: 10.1111/imr.13218

④Immunotherapy ：New evidence for the role of gut microbiota on atrial fibrillation development

Meta分析：PD-1/PD-L1抗體在不同臨床特征的晚期胃食管結(jié)合部癌患者中的效能

DOI: 10.2217/imt-2022-0305

⑤Clinical and Experimental Dermatology：Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide

選擇性核輸出蛋白1(XPO1)抑制劑塞利尼索（Selinexor）對轉(zhuǎn)移性梅克爾細胞癌(Merkel cell carcinoma, MCC)細胞株脂肪酸和膽固醇合成的影響

DOI: 10.1093/ced/llad081

⑥European Journal of Immunology：Emerging roles of host and microbial bioactive lipids in inflammatory bowel diseases

綜述：炎癥性腸病(IBD)發(fā)病機制相關(guān)的腸道脂質(zhì)與宿主細胞之間的密切相互作用

DOI: 10.1002/eji.202249866

⑦靶向CLDN18.2蛋白的自體CAR-T細胞候選產(chǎn)品CT041在美啟動Ⅱ期臨床試驗，用于治療CLDN18.2陽性實體瘤

⑧高選擇性GLP-1受體小分子完全激動劑HDM1002獲FDA新藥臨床試驗（IND）批準，將開展針對成人2型糖尿病的I期臨床試驗

⑨創(chuàng)新型核苷酸前體藥物HCV NS5B RNA依賴性RNA聚合酶抑制劑奧磷布韋片獲國家藥監(jiān)局批準上市，用于成人慢性丙型肝炎病毒感染

⑩針對B細胞表面CD20抗原的人-鼠嵌合型單克隆抗體澤貝妥單抗獲批上市，用于CD20陽性彌漫大B細胞淋巴瘤

?

科學探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！